http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Abbott Launches New Initiative to Drive Diversity in Medical Research and Improve Care Among Under-Represented Populations
-
Abbott Reports Third-Quarter 2021 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance
-
Jason Sudeikis Joins Abbott, Real Madrid at New York Stock Exchange to Support Children's Health
-
Abbott and Real Madrid Team Up to Support the Health and Nutrition of Children Globally
-
Abbott Commits to Reducing Malnutrition Globally with Launch of Abbott Center for Malnutrition Solutions
-
Abbott Hosts Conference Call for Third-Quarter Earnings
-
Abbott Receives FDA Approval for Minimally Invasive Portico™ with FlexNav™ TAVR System to Treat Patients with Aortic Valve Disease
-
Abbott Declares 391st Consecutive Quarterly Dividend
-
Abbott (ABT) Acquires Walk Vascular
-
Abbott Expands Peripheral Vascular Offerings with Acquisition of Walk Vascular, LLC
-
Abbott (ABT) Says Data From Amulet LAA Occluder IDE Trial Shows Superior Left Atrial Appendage Closure
-
Late-Breaking Data Shows Abbott's Amplatzer™ Amulet™ Occluder Offers Superior Left Atrial Appendage Closure Compared to Watchman‡ Device for People With Atrial Fibrillation at Risk of Stroke
-
Abbott's (ABT) GUIDE-HF Study Data Show CardioMEMS™ Can Improve Care for Patients with Heart Failure
-
GUIDE-HF Study Data Show Abbott's CardioMEMS™ Device Can Improve Care for More Patients with Heart Failure
-
Abbott (ABT) Amplatzer Amulet Device Approved by FDA to Treat People With Atrial Fibrillation at Risk of Stroke
-
Abbott's Amplatzer™ Amulet™ Device Approved by FDA to Treat People With Atrial Fibrillation at Risk of Stroke
-
Abbott (ABT) Receives FDA Clearance for its Imaging Technology Using Artificial Intelligence for Vessels in the Heart
-
Abbott Receives FDA Clearance for its Imaging Technology Using Artificial Intelligence for Vessels in the Heart
-
Abbott's FreeStyle® Libre 2 iOS App Cleared in U.S., Providing a Seamless Digital Experience to Simplify Diabetes Management
-
New Study: Half of Americans Living with Diabetes May be Consuming Less Than the Recommended Amount of Protein, which is Associated with Greater Physical Limitations
-
Abbott Reports Second-Quarter 2021 Results
-
Abbott's (ABT) XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients
-
Abbott's XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients
-
Late-Breaking Data Demonstrate Abbott's (ABT) FreeStyle Libre System Supports Health Equity for Millions of Americans Living with Diabetes
-
Late-Breaking Data Demonstrate Abbott's FreeStyle® Libre System Supports Health Equity for Millions of Americans Living with Diabetes
-
Abbott Hosts Conference Call for Second-Quarter Earnings
-
People Who Exercise Intensely Could Improve Recovery by Adjusting Their Hydration Habits
-
Abbott Earns First-of-its-Kind Recommendation for High School STEM Interns to Receive College Credit
-
AtriCure Names Two New Members to the Board of Directors
-
Abbott Declares 390th Consecutive Quarterly Dividend
-
Abbott Confirms Capacity to Support Expanded Use of HeartMate 3™ Heart Pump
-
Abbott (ABT) Updated FY21 EPS Guidance Misses Consensus
-
Abbott Issues Updated 2021 Outlook
-
Abbott Receives CE Mark for Navitor™, the Latest-Generation Transcatheter Aortic Valve Implantation (TAVI) System to Treat Aortic Stenosis
-
Abbott Seeks Better Treatment Options for Patients with Both Atrial Fibrillation and Heart Failure with New Trial
-
Abbott Reports First-Quarter 2021 Results
-
Abbott (ABT) Begins Shipping BinaxNOW COVID-19 Ag Self Test to Retailers Today
-
Abbott Begins Shipping BinaxNOW™ COVID-19 Ag Self Test to Retailers Today
-
World's Fastest Marathoner Eliud Kipchoge Uses Abbott's Libre Sense at NN Mission Marathon Qualifier Race for the Olympic Games
-
Abbott (ABT) Receives CE Mark Approval for Next-Generation TriClip Device, Offering New Innovations for Tricuspid Heart Valve Repair
-
Abbott Receives CE Mark Approval for Next-Generation TriClip™ Device, Offering New Innovations for Tricuspid Heart Valve Repair
-
Abbott's (ABT) XIENCE Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy (DAPT) for High Bleeding Risk Patients
-
Abbott's XIENCE™ Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy (DAPT) for High Bleeding Risk Patients
-
Abbott's BinaxNOW™ Rapid Antigen Self Test Receives FDA Emergency Use Authorization for Asymptomatic, Over-the-Counter, Non-Prescription, Multi-Test Use
-
Abbott Hosts Conference Call for First-Quarter Earnings
-
Abbott Announces its Pandemic Defense Coalition: A Global Network of Expert Collaborators Designed To Help Prevent Future Pandemics, Currently Searching for COVID-19 Variants
-
Abbott Introduces NeuroSphere™ Virtual Clinic, First-of-its-Kind Remote Neuromodulation Patient-Care Technology in the U.S.
-
Abbott (ABT) Receives FDA EUA for Laboratory PCR Assay That Detects and Differentiates SARS-CoV-2, Flu A, Flu B and RSV
-
Abbott Receives FDA EUA for Laboratory PCR Assay That Detects and Differentiates SARS-CoV-2, Flu A, Flu B and RSV in One Test - and FDA EUA for Asymptomatic Usage of Alinity m COVID-19 Test
-
Abbott Researchers Find Rare Group of People With Controlled HIV Who Could Be a Key To Unlocking Cure
